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Dear Editor,
We thank Lockwood et al. for their comments on our article
‘Effectiveness of single-dose rifampicin after BCG vaccination to
prevent leprosy in close contacts of patients with newly
diagnosed leprosy: A cluster randomized controlled trial’
(Richardus et al., 2019), and greatly appreciate the opportunity
to reply.
First, the authors compare the MALTALEP trial and the COLEP
trial (Moet et al., 2008), because both trials address chemopro-
phylaxis in leprosy with single-dose rifampicin (SDR). Yet there are
crucial differences that render direct comparison precarious. The
COLEP trial examined the effectiveness of SDR (alone) given to
contacts of leprosy patients in and outside the household. Overall,
a signiﬁcant reduction in the incidence of leprosy of 57% (95% CI:
33–72%; P = 0.0002) was seen. This result was observed after two
years and decreased the incidence of leprosy among the contacts to
the incidence of leprosy in the general, untreated population, and
this was sustained at 4- and 6-years follow-up. The authors’
remark that “The COLEP trial identiﬁed that the short-term beneﬁts of
SDR were only signiﬁcant in more distant contacts of index cases” is
simply not factual. In contrast, the beneﬁt of SDR was long-lasting
and the statistically signiﬁcant primary outcome measure of 57%
applied to all contacts collectively. For a detailed explanation of the
COLEP trial we refer to our previous communication (Richardus
and Smith, 2018).
A decade later, the MALTALEP trial had a very speciﬁc context,
different from the COLEP trial: it was based on the observation that
BCG vaccination provided to contacts of leprosy patients in the long
term had shown a protective effect against leprosy. However, the
possibility of leprosy appearing during the ﬁrst year after vaccina-
tion, before BCG’s protectionwas effective, needed further study. The
aim of the MALTALEP trial was to determine whether possible excess
cases in the ﬁrst year after immunoprophylaxis (with BCG) could be
prevented with chemoprophylaxis (with SDR) without affecting
BCG’s protective effect.Thus, the results of the MALTALEP trialshould
be considered in this light, where contacts were ﬁrst given BCG, and
subsequently SDR, in one arm of the trial. Thus, contacts receiving
SDR in this study were immunologically different from those
receiving this form of chemoprophylaxis in the COLEP study.
Furthermore, the results are confounded because one third of all
new leprosy cases among contacts arising after BCG appeared
(unexpectedly) already 8–12 weeks after BCG vaccination, and
(crucially!) before the administration of SDR. The primary outcome
measure of new leprosy cases at 1 and 2 years was not signiﬁcantly
different (at a level of 5%) between the two arms of the trial.https://doi.org/10.1016/j.ijid.2020.01.052
1201-9712/© 2020 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).In the MALTALEP article we described the reduction in PB
leprosy (most of our new patients) of 42% in the SDR arm as
notable, although not statistically signiﬁcant due to insufﬁcient
statistical power. Regarding MB leprosy, we indeed found more
cases at 1- and 2-years follow-up in the SDR arm of the trial
(5 vs. 3 and 6 vs. 0, respectively). This is certainly peculiar.
Importantly, the numbers are very low, and we hesitate to draw
any conclusions on ﬁndings of secondary subgroup analysis,
particularly about clinical relevance (Burke et al., 2015). Further-
more, MB was diagnosed initially by lesion count according to the
WHO classiﬁcation system and subsequently tested for bacterial
index (BI) by slit skin smear. Of all MB cases in the MALTALEP trial
(before and after SDR intervention), only one case had a BI of
2+ (classiﬁed as borderline lepromatous leprosy). All others were
negative (BI zero) and classiﬁed as borderline tuberculous leprosy
(BT).
The authors end with a sweeping conclusion that “the evidence
for SDR as a strategy to prevent leprosy or achieve the target of zero
transmission of M. leprae remains limited”. We hope to have made
clear that this opinion cannot be based on the ﬁndings of the
MALTALEP trial, because this trial was primarily about the
possibility of SDR augmenting the immunoprophylactic effect of
BCG vaccination. For more information on chemoprophylaxis with
SDR we refer to the 2018 WHO Guidelines for the Diagnosis,
Treatment and Prevention of Leprosy, in which a recommendation
for chemoprophylaxis with SDR is given based on the GRADE
process (Anonymous, 2018).
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